Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The Study of Quadruple Therapy Quercetin, Zinc, Metformin, and EGCG as Adjuvant Therapy for Early, Metastatic Breast Cancer and Triple-negative Breast Cancer, a Novel Mechanism

NCT05680662 is registered in ClinicalTrials.gov with Ministry of Health, Saudi Arabia as lead sponsor.

NCT NCT05680662
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05680662 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The Study of Quadruple Therapy Quercetin, Zinc, Metformin, and EGCG as Adjuvant Therapy for Early, Metastatic Breast Cancer and Triple-negative Breast Cancer, a Novel Mechanism
Lead sponsor
Ministry of Health, Saudi Arabia
Phase
Phase 1
Overall status
Unknown status
Start date
January 1, 2023
Completion date
January 31, 2024
Enrollment
200 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer female, triple negative breast cancer